Inovio's new Website Supports Novel Gene Expression Technology
News Mar 08, 2007
Inovio Biomedical Corporation, which is focused on the development of DNA vaccines and a solid tumor ablation therapy, announced that it has launched the website www.GeneSwitch.com to provide extensive technical information on Inovio’s gene regulation technology that can allow researchers to regulate, via administration of an orally available compound, the intensity and duration of gene expression from genes delivered to cells or animals.
The GeneSwitch® gene regulation technology is currently licensed for research purposes to Bayer Schering Pharma AG, GlaxoSmithKline, Organon, Senomyx, Wyeth, and Genzyme and is available in a kit form for academic research from Invitrogen.
“The GeneSwitch® regulation system used in combination with the efficient transfection observed using our proprietary electroporation technology is an attractive and convenient way to achieve gene delivery and then control resulting gene expression,” noted Avtar Dhillon, president and CEO of Inovio.
“This total solution would be particularly useful for research purposes and could potentially be used to treat protein deficiency diseases such as anemia, which results from erythropoietin (EPO) deficiency, and hemophilia, which results from factor IX deficiency.”